EAMS Scientific Opinion: polatuzumab vedotin with bendamustine and rituximab for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in adults not eligible for haematopoietic stem cell transplant

This updated positive scientific opinion was issued to Roche Products Limited and includes a public assessment report, and a treatment protocol for healthcare professionals and for patients.


Medicines and Healthcare products Regulatory Agency